Diabetes antibody standardization program: First evaluation of assays for autoantibodies to IA-2β

Diabetes Care

Volumn 34, Issue 11, 2011, Pages 2410-2412

  Schlosser, Michael ^a   Mueller, Patricia W ^b   Achenbach, Peter ^c   Lampasona, Vito ^d   Bingley, Polly J ^e  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d SAN RAFFAELE HOSPITAL   (Italy)

^e UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; ISLET ANTIGEN 2 BETA ANTIBODY; UNCLASSIFIED DRUG; RECEPTOR LIKE PROTEIN TYROSINE PHOSPHATASE;

ANTIBODY DETECTION; ANTIBODY SCREENING; ANTIBODY TITER; AREA UNDER THE CURVE; ARTICLE; BINDING ASSAY; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; IMMUNOASSAY; INSULIN DEPENDENT DIABETES MELLITUS; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; BLOOD; CASE CONTROL STUDY; EVALUATION; FEMALE; GOOD LABORATORY PRACTICE; IMMUNOLOGY; MALE; STANDARD;

AREA UNDER CURVE; AUTOANTIBODIES; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; IMMUNOASSAY; LABORATORY PROFICIENCY TESTING; MALE; RECEPTOR-LIKE PROTEIN TYROSINE PHOSPHATASES, CLASS 8; REFERENCE STANDARDS; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 84857079682     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc11-1161     Document Type: Article

References (11)

1. Bingley PJ, Bonifacio E, Mueller PW. Diabetes Antibody Standardization Program: first assay proficiency evaluation. Diabetes 2003;52:1128-1136 (Pubitemid 36523346)
2. Törn C,Mueller PW, SchlosserM, Bonifacio E, Bingley PJ; Participating Laboratories. Diabetes Antibody Standardization Program: evaluation of assays for autoantibodies to glutamic acid decarboxylase and islet antigen-2. Diabetologia 2008;51:846-852
3. Schlosser M, Mueller PW, Törn C, Bonifacio E, Bingley PJ; Participating Laboratories. Diabetes Antibody Standardization Program: evaluation of assays for insulin autoantibodies.Diabetologia 2010;53:2611-2620
4. Achenbach P, Schlosser M, Williams AJK, et al. Combined testing of antibody titer and affinity improves insulin autoantibody measurement: Diabetes Antibody Standardization Program. Clin Immunol 2007;122:85-90 (Pubitemid 46026696)
5. Bonifacio E, Lampasona V, Bingley PJ. IA-2 (islet cell antigen 512) is the primary target of humoral autoimmunity against type 1 diabetes-associated tyrosine phosphatase autoantigens. J Immunol 1998;161:2648-2654 (Pubitemid 28397086)
6. Hoppu S, Härkönen T, Ronkainen MS, Akerblom HK, Knip M; Childhood Diabetes in Finland Study Group. IA-2 antibody epitopes and isotypes during the prediabetic process in siblings of children with type 1 diabetes. J Autoimmun 2004;23:361-370 (Pubitemid 39574811)
7. Decochez K, De Leeuw IH, Keymeulen B, et al.; Belgian Diabetes Registry. IA-2 auto-antibodies predict impending type I diabetes in siblings of patients. Diabetologia 2002;45:1658-1666 (Pubitemid 35478135)
8. Achenbach P, Warncke K, Reiter J, et al. Stratification of type 1 diabetes risk on the basis of islet autoantibody characteristics. Diabetes 2004;53:384-392 (Pubitemid 38174554)
9. Christie MR, Genovese S, Cassidy D, et al. Antibodies to islet 37k antigen, but not to glutamate decarboxylase, discriminate rapid progression to IDDM in endocrine autoimmunity. Diabetes 1994;43:1254-1259 (Pubitemid 24361193)
10. Achenbach P, Bonifacio E, Williams AJK, Ziegler AG, Gale EAM, Bingley PJ; ENDIT Group. Autoantibodies to IA-2b improve diabetes risk assessment in high-risk relatives. Diabetologia 2008;51:488-492
11. De Grijse J, Asanghanwa M, Nouthe B, et al.; Belgian Diabetes Registry. Predictive power of screening for antibodies against insulinoma-associated protein 2 beta (IA-2beta) and zinc transporter-8 to select first-degree relatives of type 1 diabetic patients with risk of rapid progression to clinical onset of the disease: implications for prevention trials. Diabetologia 2010;53:517-524